STUDY PROTOCOL
CIVCAP

A) TRIAL IDENTIFICATION CLINICAL	
SPONSOR CODE NUMBER: ICO-2018-12	
TRIAL TITLE: Single-Center Prospective Non-Interventional Study of Quantitative and Qualitative Use of Dietary Supplements in Addition to Anticancer Chemotherapy in Patients with Early Breast Cancer Managed in a Day Hospital Setting	
ABBREVIATED TITLE: CIVCAP	
COORDINATOR: Dr. Emmanuelle BOURBOULOUX **COORDINATOR**: Dr. Laurence DUMAS	
ESTIMATED NUMBER OF CENTERS: 1	**NUMBER OF PATIENTS**: 200

B) IDENTIFICATION OF THE PROMOTER
NAME OF ORGANIZATION: ICO, DRCI-Promotion Unit
CONTACT PERSON: **Ms. Nadia ALLAM** Tel: 02 40 67 98 26 Nadia.allam@ico.unicancer.fr

C) GENERAL INFORMATION ABOUT THE TRIAL
INDICATION: Patients treated in a day hospital (DH) setting for intravenous (IV) chemotherapy for breast cancer in the neoadjuvant and/or adjuvant setting.
METHODOLOGY: The study has the following characteristics: • single-center, • prospective, • open-label, • non-randomized

PRIMARY OBJECTIVE AND ENDPOINT:

Primary objective:

To quantitatively assess the use of dietary supplements by patients during IV chemotherapy.

Primary Endpoint:

Proportion of patients using dietary supplements, defined as the number of patients taking dietary supplements divided by the total number of patients.

SECONDARY OBJECTIVES AND ENDPOINTS

Secondary Objectives:

- To evaluate the impact of Desmodium use on liver function test outcomes between the first and last chemotherapy cycles.
- To characterize the dietary supplements used (type, timing of use, and intended purpose).
- To identify the prescriber of the dietary supplements.
- To describe the modalities of supply and administration of these dietary supplements.
- To assess how information about dietary supplement use is communicated to healthcare professionals.

Secondary Endpoints:

- Percentage of patients experiencing hepatic cytolysis during chemotherapy.
- Percentage of patients experiencing hepatic cytolysis during chemotherapy who are taking Desmodium.
- Percentage of patients taking Desmodium.
- Distribution of the different types of dietary supplements used.
- Patterns of dietary supplement use (timing and frequency).
- Reasons for dietary supplement use.
- Modes of supply/acquisition of dietary supplements.
- Modalities of communication with healthcare professionals regarding dietary supplement use.

INCLUSION CRITERIA:

1. Age ≥ 18 years.
2. Breast cancer treated with intravenous (IV) chemotherapy.
3. Neoadjuvant and/or adjuvant setting.
4. Inclusion at the last chemotherapy cycle.
5. Adjuvant chemotherapy administered entirely at the study site in a day hospital (DH) setting.

EXCLUSION CRITERIA:

1. Cancers other than breast cancer.
2. Metastatic disease.
3. Not all chemotherapy cycles performed at the site.
4. Patients currently undergoing treatment (i.e., not yet at the final cycle).

D) TREATMENT, PROCEDURE UNDER STUDY

- **Study Intervention/Procedure:**

To assess the impact of dietary supplement use in patients with breast cancer treated with intravenous (IV) chemotherapy.

- **Intervention/Procedure duration / Follow-up:**

Between the first and the last chemotherapy cycle.

D) STUDY IMPLEMENTATION AND CONDUCT

Patients will be enrolled consecutively as they are managed at the study site.
A dietary supplement use questionnaire is completed by all patients at the time of the last chemotherapy cycle.
Liver function tests (AST, ALT, ALP, and GGT) is performed from the first to the last chemotherapy cycle.

E) STATISTICAL CONSIDERATIONS

CALCULATION OF THE NUMBER OF SUBJECTS REQUIRED:

This is a prospective, single-arm (non-comparative) study including consecutively and exhaustively all patients treated at the center who meet the inclusion criteria. A recruitment period of 18 months is planned to establish this cohort, corresponding to an estimated enrollment of approximately 200 patients.

STATISTICAL ANALYSIS PLAN:

As this is a purely descriptive study, qualitative variables will be described using the frequencies of their respective categories along with 95% confidence intervals.
Quantitative variables, including liver function parameters (AST, ALT, alkaline phosphatase, and GGT), will be described using mean ± standard deviation, as well as median, minimum, and maximum values.
For exploratory purposes only:

Associations between qualitative variables may be assessed using Pearson's chi-square test (or Fisher's exact test when appropriate).
Comparisons of means (or medians) between selected groups of interest may be performed using Student's t-test (or the Wilcoxon test when appropriate) for two groups, and ANOVA (or the Kruskal–Wallis test) for more than two groups.

The level of statistical significance will be set at 5%. Analyses will be performed using Stata SE 13.1 (StataCorp, College Station, Texas, USA). It should be noted that these tests are exploratory and will have only indicative value, as no a priori power calculation has been performed.

F) EXPECTED DURATION OF THE TRIAL

INCLUSION PERIOD:	**18 MONTHS**
TREATMENT PERIOD:	From first to last chemotherapy treatment